OKYO Pharma joins Piper Sandler ophthalmology symposium

OKYO Pharma Limited filed a report describing its participation in the Piper Sandler 2026 Virtual Ophthalmology Symposium.

Rhea-AI Filing Summary

OKYO Pharma Limited filed a report describing its participation in the Piper Sandler 2026 Virtual Ophthalmology Symposium. The company will join a fireside chat on July 9, 2026 at 8:30 AM, featuring CEO Robert J. Dempsey and Chief Medical Officer Flavio Mantelli.

OKYO is a clinical-stage biopharma company focused on innovative therapies for neuropathic corneal pain and inflammatory eye diseases. It recently completed a successful Phase 2 trial of its lead drug urcosimod in neuropathic corneal pain and plans a 150-patient Phase 2b/3 multiple-dose study.

Key Figures

Symposium date and time: July 9, 2026 at 8:30 AM Phase 2b/3 study size: 150 patients Exhibit number: 99.1 +1 more

4 metrics

Symposium date and time July 9, 2026 at 8:30 AM Piper Sandler 2026 Virtual Ophthalmology Symposium

Phase 2b/3 study size 150 patients Planned Phase 2b/3 multiple-dose urcosimod study in NCP

Exhibit number 99.1 News announcement attached to the Form 6-K

Registration statement number 333-293145 Form F-3 into which the report is incorporated by reference

Key Terms

neuropathic corneal pain, Phase 2b/3, clinical-stage biopharmaceutical, Virtual Ophthalmology Symposium, +1 more

5 terms

neuropathic corneal pain medical

"developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases"

Neuropathic corneal pain is chronic, often severe eye pain caused by damage or malfunction in the tiny nerves of the cornea, where the eye surface can feel burning, stinging, or like something is in it despite little visible damage. It matters to investors because it represents a persistent, hard-to-treat medical need that drives demand for new drugs, diagnostics, devices and regulatory approvals, similar to how fixing a frayed electrical wire stops false alarm signals.

Phase 2b/3 medical

"plans to initiate a 150-patient Phase 2b/3 multiple-dose study of urcosimod"

A phase 2b/3 trial is a combined late-stage clinical study that first refines the best dose and measures how well a treatment works (phase 2b) then expands to a larger, definitive test of safety and effectiveness needed for regulatory approval (phase 3). For investors, results from a phase 2b/3 act like a dress rehearsal that turns into opening night: positive, well-controlled outcomes substantially raise the chance of approval and future sales, while failures can sharply reduce a drug’s value.

clinical-stage biopharmaceutical financial

"a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain"

A clinical-stage biopharmaceutical is a company that is developing medicines or biological treatments that are currently being tested in people in clinical trials to assess safety and effectiveness. For investors it signals a higher-risk, higher-reward profile: progress through human testing and regulatory milestones can sharply increase value if results are positive, while failed trials can wipe out expected future revenue — like a prototype that must prove it works before it can be sold widely.

Virtual Ophthalmology Symposium other

"participation at the Piper Sandler Virtual Ophthalmology Symposium being held on Thursday, July 9, 2026"

Registration Statement on Form F-3 regulatory

"incorporated by reference into the Company’s Registration Statement on Form F-3"

A registration statement on Form F-3 is a streamlined filing used by eligible foreign companies to register securities for sale in the U.S., often as a “shelf” that lets them offer shares quickly when market conditions are right. For investors it matters because it signals that the company can raise capital on short notice—potentially increasing liquidity but also the risk of share dilution if new stock is issued—similar to a company keeping a pre-approved credit line ready to use.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did OKYO (OKYO) announce in this Form 6-K filing?

OKYO Pharma announced its participation in the Piper Sandler 2026 Virtual Ophthalmology Symposium. The company will join a fireside chat focused on its eye disease programs, highlighting leadership participation and ongoing development of therapies for neuropathic corneal pain and inflammatory eye diseases.

When will OKYO (OKYO) present at the Piper Sandler Virtual Ophthalmology Symposium?

OKYO Pharma is scheduled to participate in a fireside chat on Thursday, July 9, 2026 at 8:30 AM. The session is part of the Piper Sandler 2026 Virtual Ophthalmology Symposium and will be held entirely online for interested participants and stakeholders.

Who will present for OKYO (OKYO) at the Piper Sandler ophthalmology event?

OKYO Pharma’s presenters are Chief Executive Officer Robert J. Dempsey and Chief Medical Officer Flavio Mantelli, MD, PhD. The fireside chat will be moderated by Biren Amin, Managing Director, Healthcare Equity Research at Piper Sandler & Co., during the virtual symposium.

What is OKYO Pharma (OKYO) developing for neuropathic corneal pain?

OKYO Pharma is developing urcosimod as a lead investigational therapy for neuropathic corneal pain. The company recently completed a successful Phase 2 trial and plans to initiate a 150-patient Phase 2b/3 multiple-dose study in neuropathic corneal pain in the first half of this year.

What stage of development is OKYO Pharma (OKYO) in for its eye therapies?

OKYO Pharma is a clinical-stage biopharmaceutical company. It has completed a Phase 2 trial of urcosimod in neuropathic corneal pain and is planning a 150-patient Phase 2b/3 multiple-dose study, while continuing to develop therapies for neuropathic corneal pain and inflammatory eye diseases.

Where are OKYO Pharma (OKYO) shares listed for trading?

OKYO Pharma’s ordinary shares are listed for trading on the Nasdaq Capital Market under the symbol OKYO. The company is focused on developing innovative treatments for neuropathic corneal pain and inflammatory eye diseases as a clinical-stage biopharmaceutical issuer.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/07/2026 - 07:00 AM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

July 2026

Commission File Number: 001-41386

OKYO Pharma LTD

(Exact Name of Registrant as Specified in Its Charter)

9^th Floor

107 Cheapside

London

EC2V 6DN

(Address of registrant’s principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

On July 7, 2026, OKYO Pharma LTD (the “Company”) issued this 6K announcing participation at the Piper Sandler Virtual Ophthalmology Symposium being held on Thursday, July 9, 2026.

The Announcement is furnished herewith as Exhibit 99.1 to this Report on Form 6-K. The information in the attached Exhibits 99.1 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that Section, This report on Form 6-K is hereby incorporated by reference into the Company’s Registration Statement on Form F-3 (Reg. No. 333-293145)

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	OKYO Pharma LTD
Date: July 7, 2026	By:	/s/ Keeren Shah
	Name:	Keeren Shah
	Title:	Chief Financial Officer

3

EXHIBIT INDEX

Exhibit No.		Description
99.1		News Announcement, dated July 7, 2026

4

Exhibit 99.1

OKYO Pharma to Participate in a Fireside Chat at Piper Sandler 2026 Virtual Ophthalmology Symposium

London and New York, NY, July 7, 2026. OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced participation at the Piper Sandler Virtual Ophthalmology Symposium being held on Thursday, July 9, 2026.

Details of the event are as follows:

Presenters: Robert J. Dempsey, Chief Executive Officer, Flavio Mantelli MD, PhD, Chief Medical Officer

Date/Time: Thursday, July 9 at 8:30 AM ET

Moderator: Biren Amin, Managing Director, Healthcare Equity Research, Piper Sandler & Co.

Location: Virtual

About OKYO Pharma

OKYO Pharma Limited (Nasdaq: OKYO) is a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP) and inflammatory eye diseases, with ordinary shares listed for trading on the Nasdaq Capital Market. OKYO is focused on the discovery and development of novel molecules to treat neuropathic corneal pain and other ocular diseases. OKYO recently completed a successful phase 2 trial of its flagship drug urcosimod in patients with NCP and plans to initiate a 150-patient Phase 2b/3 multiple-dose study of urcosimod to treat NCP in the first half of this year.

For further information, please visit www.okyopharma.com.

For further inquiries:

OKYO Pharma Ltd

Paul Spencer

Business Development and Investor Relations

+44 (0) 207 495 2379

Email: info@okyopharma.com

Filing Exhibits & Attachments

2 documents

Press Releases

• EX-99.1 EX-99.1 8.8 KB
• EX-99 GRAPHIC 13.8 KB